Cancer procoagulant in patients with adenocarcinomas
Maciej Kaźmierczak(Silesian University of Technology), Mieczysław Komarnicki(Poznan University of Medical Sciences), Krzysztof Lewandowski(Poznan University of Medical Sciences), Elźbieta Skrzydlewska(Adam Mickiewicz University in Poznań), Marek Z. Wojtukiewicz(Medical University of Białystok), Anna Łojko(Poznan University of Medical Sciences), Krystyna Zawilska(Poznan University of Medical Sciences), Edyta Kołacz(Poznan University of Medical Sciences), Z Turowiecka(Poznan University of Medical Sciences)
Cited by 25
Related Papers
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Antioxidative and Anti-Inflammatory Activity of Ascorbic Acid
|Antioxidants|2022|374
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
|Blood Advances|2020|109
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
|Journal of Clinical Oncology|2022|93
Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR
|International Journal of Oncology|2017|80